Ajanta Pharma Ltd reported a strong financial performance for the fourth quarter ended March 31, registering an 18.4 percent year-on-year increase in consolidated net profit to Rs. 266.7 crore. The growth was primarily fueled by robust expansion in its US generics business, a key revenue driver. The company had posted a net profit of Rs. 225.26 crore in the corresponding period last year. Revenue from operations also rose significantly to Rs. 1,421.64 crore from Rs. 1,170.41 crore, underscoring improved market traction and operational efficiency across key geographies.